PKI-166
CAY-21896-5 5 mg
Data Sheet: 
SDS:
SDS:
CAS
187724-61-4
Formulation
A crystalline solid
Purity
≥98%
MW
330,4
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
An inhibitor of EGFR (IC50 = 0.0007 µM for the intracellular kinase domain); selective for the EGFR intracellular kinase domain over the serine/threonine kinases PKC-α and Cdc2/cyclin B (IC50s = >100 and 78 µM, respectively), as well as FLK, c-Met, and Tek (IC50 = >1 µM for all), but does inhibit c-Src, c-Abl, VEGFR2/KDR, FLT1, and c-Kit (IC50s = 0.103, 0.028, 0.327, 0.962, and 2.21 µM, respectively); enhances the cytotoxicity of gemcitabine in L3.6pl cells; reduces tumor growth and metastasis and increases survival in an L3.6pl mouse xenograft model at 100 mg/kg per day with additive effects when administered in combination with gemcitabine; reduces tumor growth and inhibits angiogenesis in an SN12-PM6 human renal cell carcinoma mouse orthotopic model
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
